De research unit is een onderdeel van de oncologische afdeling binnen het UZA. Het doel van de research unit is nieuwe, betere en steeds meer doeltreffendere behandelingen vinden om kankerpatiënten te behandelen. Klinische studies zijn hiervoor de beste methode. Tijdens deze klinische studies kunnen onze onderzoekers bepalen welke behandelingen veiliger, effectiever en beter zijn dan huidige behandelingen. De research unit bestaat uit artsen, studie coördinatoren, logistieke medewerkers, studie verpleegkundigen, pathologen en administratieve medewerkers.
Heb je vragen over de studies binnen de research unit? Neem gerust contact met ons op via 03 821 55 80, 03 821 53 07 of via research [dot] oncologie [at] uza [dot] be.
Title | Tumortype | Line of therapy | Study information | Status | Register |
STARTRK-2: Basket study of Entrectinib for patients with tumors that harbor NTRK1/2/3, ROS1 or ALK gene rearrangements. | Solid | All |
|
Open | NCT02568267 |
TVEC: phase 1b/2 of Talimomgene Laherparepvec injected into liver tumors alone and in combination with Pembrolizumab |
|
≥1L |
TVEC intrahepatic Q3W - Pembrolizumab Q3W IV |
Open | NCT02509507 |
alloSHRINK: Phase 1 of CYAD-101 (CAR-T cells) in combination with FOLFOX in mCRC | CRC | >1L, documented PD under FOLFIRI |
|
Open | NCT03692429 |
Precision 2: phase 2 with afatinib in tumors with EGFR, HER2 or HER3 mutation followed by addition of paclitaxel to afatinib at disease progression | Solid | >1L |
|
Open | NCT03810872 |
AMG404: A Phase 1 study with AMG 404 (a PD-1 antibody) in patients with advanced solid tumors |
|
All, no prior anti-PD-(L)1 or CTLA-4 |
|
Slots | NCT03853109 |
CVPM087A2101: Phase Ib study of gevokizumab in combination with standard of care anti-cancer therapies in patients with metastatic colorectal cancer, gastroesophageal cancer and renal cell carcinoma |
|
|
|
Open | NCT03798626 |
MiMe-A: Multiorgan Metabolic imaging response assessment of Abemaciclib |
Esophageal squamous cell carcinoma | All |
|
Slots | NCT03339843 |
AMG510: Phase 1/2 open label study with AMG510 monotherapy in subjects with advanced solid tumors with KRAS p.G12C mutation |
Solid | Multiple |
|
Closed |
|
RAGNAR: A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and Selected FGFR Gene Alterations |
Solid Tumors | >1L |
|
Open | |
KISIMA-01: Phase Ib Study to evaluate the safety, tolerability and anti-tumor activity of ATP128, with or without BI 754091 in patients with stage IV CRC |
CRC | 2L |
|
Slots |
|
BLU-667: A Phase 1/2 study of the highly-selective RET inhibitor, BLU-667, in patients with thyroid cancer, NSCLC and other advanced solid tumors |
|
|
|
Open | |
MIV-818: A Phase 1/2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of MIV-818 in Patients with Liver Cancer Manifestations |
HCC, iCCA, colon, rectum and gastrid cancer |
All |
|
Slots |
|
MCLA-145-CL01: A Phase 1, Open-label, Dose-escalation study of MCLA-145 in participants with advanced or metastatic malignancies |
All solid tumors |
<=4L |
|
Slots |
|
SYD985.004:A Phase 1 study with the antibody-drug conjugate SYD985 in combination with Niraparib in patients with HER2-expressing locally advanced or metastatic solid tumors |
All solid tumors |
All |
|
Slots | |
GO40987: A phase I, multicenter, open-label, preoperative, short-term window study of GDC-9545 in postmenopausal women with Stage I-III operable, estrogen receptor-positive breast cancer. |
Breast |
1L |
|
Open |
|
INCB86550-102: A Phase 1 study with INCB086550 in patients with advanced solid tumors |
Other tumor types with approval of Medical Monitor |
|
|
Open | |
eNRGy: Full molecular testing by RNA/DNA next generation sequencing to detect RNA/DNA alterations (including NRG1 fusions) |
Locally advanced/metastatic pancreatic adenocarcinoma | All |
|
Open | |
BOT112-02: Phase IIa open-label clinical study of intratumoural administration of BO-112 in combination with pembrolizumab in subjects with liver metastasis from colorectal cancer or gastric/gastro-oesophageal junction cancer. |
|
|
|
Hold | NCT04508140 |
Precision-2 olaparib: Efficacy of Olaparib in advanced cancers occurring in patients with germline mutations or somatic tumor mutations in homologous recombination genes. |
|
prior SOC |
|
Open | NCT03967938 |
MATTERS: A mono-centric, first in-human (FIH), safety and preliminary efficacy study of (neo)adjuvant, model-based, whole-body hyperthermia (WBHT) treatment in advanced solid cancer patients or stage IV (TxNxM1) metastatic pancreatic adenocarcinoma patients |
Solid - stage IV | All |
|
Open | NCT04467593 |
INCB99280-112: A Phase 1 Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Select Advanced Solid Tumors |
|
|
|
Slots | NCT04242199 |
EZH-1201: A Phase I, Open-label Multi-dose Pharmacokinetic and Safety Study of Oral Tazemetostat in Subjects with Moderate and Severe Hepatic Impairment with Advanced Malignancies. |
All tumortypes with:
|
|
|
Slots |
NCT04241835 |
BP42169: An Open-Label Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7293583, A TYRP1-Targeting CD3 T-Cell Engager, in Participants With Metastatic Melanoma |
TYRP-positive melanoma |
|
|
Open | |
ARRAY 818-103: An Open-label Phase 1 Study to Evaluate Drug-Drug Interactions of Agents Co-Administered With Encorafenib and Binimetinib in Patients With BRAF V600-mutant Unresectable or Metastatic Melanoma or Other Advanced Solid Tumors |
BRAF V600E/V600K mutated solid tumors |
|
|
Open | |
TRIDENT-1: A Phase 1/2, Open-Label Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1) |
|
|
|
Open | |
JZLA (EMBER): A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination With Anticancer Therapies for Patients With ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers |
|
|
|
Slots | |
BAYER20810 (LOXO-17005): A Phase 1/2 Study of the TRK Inhibitor Selitrectinib in Adult and Pediatric Subjects With Previously Treated NTRK Fusion Cancers |
|
|
|
Slots |
|
FIDES-03: Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma |
|
|
|
Open |
Title | Tumortype | Line of therapy | Study information | Status | Register |
NATALEE: A Phase 3, Randomized, Open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as an adjuvant treatment in patients with HR positive, HER2-negative, early breast cancer. | HER2-, HR+ | Adjuvant |
|
Open | NCT03701334 |
DESTINY-06: A Phase 3, Randomized, Open-Label Study of Trastuzumab Deruxtecan (T-DXd) vs. Investigatior's Choice Chemotherapy in HER2-low, Hormone Receptor Positive Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy in the Metastatic Setting. |
HR + and HER2 low or - : - IHC 2+/ISH- - IHC 1+/ISH- or untested - IHC 0/ISH- or untested |
1 L chemo |
|
Open | NCT04494425 |
The AURORA PROGRAM: Aiming to Understand the Molecular Aberrations in Metastatic Breast Cancer | All | 1-2L |
|
Hold | NCT02102165 |
CAPitello291: Phase II study of Capivasertib + Fulvestrant vs Placebo + Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer | HER2-/ER+ | 1-3L |
|
Open | NCT04305496 |
WO41554/INAVO120: Phase III, double-blind, placebo-controlled study evaluating the efficacy and safety of GDC-0077/Placebo plus Palbociclib and Fulvestrant in patients with PIK3CA-mutant, Hormone Receptor-Positive, Her2-Negative locally advanced or metastatic breast cancer. | HER2-/HR+ | 1L |
|
Open | NCT04191499 |
CONTESSA TRIO: Phase II study of Tesetaxel + Three Differend PD-(L)1 Inhibitors in Patients with Triple-Negative, Locally Advanced or Metastatic Breast Cancer and Tesetaxel Monotherapy in Elderly Patients with HER2 Negative, Locally Advanced or Metastatic Breast Cancer. | HER2- | 1L |
|
Open | NCT03952325 |
APTneo: Atezolizumab, Pertuzumab and Trastuzumab with chemotherapy as neoadjuvant treatment of HER2 positive early high-risk and locally advanced breast cancer. | HER2+ | Neo-adjuvant, adjuvant |
|
Open | NCT03595592 |
MK-3475-756: A randomized, double-blind, phase 3 study of Pembrolizumab vs Placebo in combination with neoadjuvant chemotherapy and adjuvant endocrine therapy for the treatment of high-risk early-stage ER+/HER2– breast cancer (KEYNOTE-756). |
ER+/HER2- | Neo-adjuvant, adjuvant |
|
Open | NCT03725059 |
Title | Tumortype | Line of therapy | Study information | Status | Register |
DENOSUMAB/DICER: A neoadjuvant phase II study assessing the therapeutic potential of RANK/L signaling inhibition in patients with primary and recurrent squamous carcinoma of the uterine cervix | CERVIX | new diagnosis or central recurrent invasive |
|
Open | |
FUCHSIA: An open-label, single arm, prospective, multi-center, tandem two stage designed, phase II study to evaluate the efficacy of Fulvestrant in women with recurrent/metastatic estrogen receptor positive gynecological malignancies |
UTERUS, ENDOMETRIUM & OVARIUM | 2-3 line hormonal therapy |
|
Open | NCT03926936 |
Title | Tumortype | Line of therapy | Study information | Status | Register |
ASPIRIN: A Randomised, double–blind, placebo-controlled Trial of Aspirin to prevent Recurrence | Colon Cancer | Adjuvant |
|
Open | NCT03464305 |
SPOTLIGHT: A Double-Blind, Randomized, efficacy Study of Zolbetuximab (IMAB362) Plus mFOLFOX6 Compared with Placebo Plus mFOLFOX6 |
Gastric cancer + GEJ | 1 |
|
Open | NCT03504397 |
CAIRO 5: Treatment Strategies in Colorectal Cancer Patients With Initially Unresectable Liver-only Metastases |
Colon cancer + Liver metastasis | 1 |
|
Open | NCT02162563 |
TOPGEAR: Trial of Preoperative Therapy for Gastric and Esophagogastric Junction Adenocarcinoma |
Resectable Gastric cancer + GEJ | Neo-adjuvant |
|
Open | NCT01924819 |
DZB-CS-301: A pivotal study of derazantinib in patients with inoperable or advanced intrahepatic cholangiocarcinoma |
Intrahepatic CholangioCA |
2 |
|
Open | NCT03230318 |
TIGeR-PaC: Intra-arterial Gemcitabine vs. Continuation of IV Gemcitabine plus Nab-Paclitaxel following Induction with sequential IV Gemcitabine plus Nab-Paclitaxel and Radiotherapy. |
Unresectable Locally Advanced Pancreatic Cancer |
induction |
|
Open | NCT03257033 |
LEAD-IN FOLICOLOR Trial: Detection of progressive disease in metastatic colorectal cancer patients by NPY methylation in liquid biopsies. |
Unresectable metastatic colorectal cancer |
1 |
|
Open | |
PROMETCO |
Metastatic colorectal cancer |
3 |
|
Open | NCT03935763 |
CL3-95005-007 |
Refractory metastatic colorectal cancer | 3 |
|
Open | NA |
MOUNTAINEER |
Unresectable or metastatic Colorectal Cancer |
>3 |
|
Open | NCT03043313 |
YO42137 |
Unresectable locally advanced esophageal squamous cell carcinoma | 1 |
|
Open | NCT04543617 |
QBGJ398-301 (PROOF trial) |
Advanced/metastatic or inoperable cholangioCA | 1 |
|
Open | NCT03773302 |
MK3475-966 |
Advanced and/or unresectable biliary tract carcinoma |
1 |
|
Open | NCT04003636 |
MK7339-003 |
Unresectable or metastatic colorectal cancer without progression on 1ste line FOLFOX |
1 |
|
Open | NCT04456699 |
FRESCO-2 |
Refractory metastatic colon cancer |
>3 |
|
Expected | NCT04322539 |
D-US-60010-001 (NAPOLI-3) |
Metastatic pancreatic cancer | 1 |
|
Open | NCT04083235 |
Title | Tumortype | Line of therapy | Study information | Status | Register |
EORTC1206: A randomized phase II study to evaluate the efficacy and safety of chemotherapy (CT) vs. androgen deprivation therapy (ADT) in patients with recurrent and/or metastatic, androgen receptor (AR) expressing, salivary gland cancer (SGCs) | Salivary gland | Treatment naïve and pretreated |
|
Open | NCT01969578 |
UPSTREAM: A pilot study of personalized biomarker-based treatment strategy or immunotherapy in patients with recurrent/metastatic squamous cell carcinoma of the head and neck |
SCCHN:
|
>1L, platinum failed |
|
Open | NCT03088059 |
OpcemISA: A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study of Cemiplimab vs. the Combination of Cemiplimab With ISA101b in the Treatment of Subjects With HPV16-Positive Platin-Resistant Oropharyngeal Cancer (OPC) |
SCCHN Oropharynx HPV16+ |
1-2 L |
|
Open | NCT03669718 |
The AIM-HN: A 2 Cohort, Non-comparative, Pivotal Study Evaluating the Efficacy of Tipifarnib in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC) with HRAS Mutations (AIM-HN) |
SCCHN
|
>1L |
AIM-HN:
|
Open | NCT03719690 |
HN9: Randomized Phase II study of Cisplatin + Radiotherapy vs Durvalumab + Radiotherapy followed by Adjuvant Durvalumab vs Durvalumab + Radiotherapy followed by Adjuvant Tremelimumab and Durvalumab in Intermediate Risk HPV-Positive Locoregionally Advanced Oropharyngeal Squamous Cell Cancer |
SCCHN Oropharynx p16+ |
1L |
|
Open | NCT03410615 |
JZJB: A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Cabozantinib or Vandetanib in Patients with Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531) |
Thyroid |
1L |
|
Open | NCT04211337 |
INDUCE-4: A Phase II/ III study of GSK3359609 in combination with pembrolizumab and 5FU-platinum chemotherapy compared with placebo in combination with pembrolizumab plus 5FU-platinum chemotherapy in participants with recurrent or metastatic HNSCC |
SCCHN:
|
1L |
|
Open | NCT04428333 |
Title | Tumor Type | Line of therapy | Study information | Status | Register |
rEECur: International Randomised Controlled Trial of Chemotherapy for the Treatment of Recurrent and Primary Refractory Ewing Sarcoma | Ewing Sarcoom | >1 L |
|
Open |
Title | Tumor Type | Line of therapy | Study information | Status | Register |
ADDIT-GLIO: Adjuvant dendritic-cell immunotherapy plus temozolomide following surgery and chemoradiation in patients with newly diagnosed glioblastoma | Glioblastoma | Adjuvant |
|
Open | NCT02649582 |
ROAM: Radiation versus Observation following surgical resection of Atypical Meningioma: a randomised controlled trial | solitary atypical meningioma | Adjuvant |
|
Open |
Title | Tumor Type | Line of therapy | Study information | Status | Register |
PEACE III: A Randomized phase III trial comparing enzalutamide vs. a combination of Ra223 and enzalutamide in asymptomatic or mildly symptomatic castration resistant prostate cancer patients metastatic to bone. | Prostate cancer | >= 1L |
|
open | NCT02194842 |
CASSIOPE: Prospective noninterventional study of cabozantinib tablets in adults with advanced renal cell carcinoma following prior VEGF targeted therapy | Renal Cell Carcinoma | >= 2L |
|
Open | NCT03419572 |
AURA: Avelumab as neoadjuvant therapy in subjects with urothelial muscle invasive bladder cancers | Muscle invasive urothelial carcinoma | Neo-adjuvant |
|
Open | NCT03674424 |
Title | Tumor Type | Line of therapy | Study information | Status | Register |
Minitub: Prospective registry of Sentinel Node (SN) positive melanoma patients with minimal SN tumor burden who undergo Completion Lymph Node Dissection (CLND) or Nodal Observation. | Melanoma | 1L |
|
Open | NCT01942603 |
INITIUM: A Randomized Phase II, Open-label, Active-controlled, Multicenter Study Investigating the Efficacy and Safety of UV1 Vaccination in Combination with Nivolumab and Ipilimumab as First-line Treatment of Patients with Unresectable or Metastatic Melanoma | Melanoma | 1L |
|
Open | NCT04382664 |
IMCODE001: A Phase 2, Open-Label, Multicenter, Randomized Study of The Efficacy and Safety of RO7198457 in Combination With Pembrolizumab vs Pembrolizumab in Patients with Previously Untreated Advanced Melanoma | Melanoma | 1L |
|
Open | NCT03815058 |
POLARIS: A Phase 2, Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients With BRAFV600-Mutant Melanoma Brain Metastasis | Melanoma | 1-2L |
|
open | NCT03911869 |
De dienst thoraxoncologie is een onderdeel van het MOCA (Multidisciplinair Oncologisch Centrum Antwerpen) binnen het UZA. We behandelen patiënten met longkanker, longvlieskanker en thymustumoren. Naast standaard behandelingen bieden we ook behandelingen in studieverband aan. Het gaat hier om fase II en III klinische studies. Het doel van een klinische studie is om te onderzoeken of een nieuwe behandeling veiliger, effectiever en beter is dan huidige behandeling. Voor fase I klinische studies verwijzen we u naar de research unit.
Heb je vragen over de studies binnen de dienst thoraxoncologie? Neem gerust contact met ons op via 03 821 31 07 of via thoraxoncologie [at] uza [dot] be.
Title | Tumor Type | Line of therapy | Study information | Status | Register |
CheckMate 77T: A Phase 3, Randomized, Double-blind Study of Neoadjuvant Chemotherapy plus Nivolumab versus Neoadjuvant Chemotherapy plus Placebo, followed by Surgical Resection and Adjuvant Treatment with Nivolumab or Placebo for Participants with Resectable Stage II-IIIB NSCLC | NSCLC stage II-IIIB | Perioperative |
|
Open | NCT04025879 |
EORTC1205 Randomized Phase II Study of Pleurectomy/ Decortication (P/D) Preceded or Followed by Chemotherapy in Patients With Early Stage Malignant Pleural Mesothelioma | mesothelioma | 1L |
|
Open | NCT02436733 |
A Randomized, Open-Label Phase II/III Study With Dendritic Cells Loaded With Allogeneic Tumour Cell Lysate (PheraLys) in Subjects With Mesothelioma as Maintenance Treatment (MesoPher) After Chemotherapy (DENIM) | mesothelioma | 1L |
|
Open | NCT03610360 |
Single-arm, Multicentre, Phase II Study of Immunotherapy in Patients With Type B3 Thymoma and Thymic Carcinoma Previously Treated With Chemotherapy (NIVOTHYM) | thymoma/thymus carcinoma | >1L |
|
Hold | NCT03134118 |
INSIGHT2: A Phase II two-arm study to investigate tepotinib combined with osimertinib in MET amplified, advanced or metastatic NSCLC harboring activating EGFR mutations and having acquired resistance to prior osimertinib therapy. | NSCLC | 2L |
|
Open | NCT03940703 |
AcceleRET: A Randomized, Open-Label, Phase 3 Study of Pralsetinib vs SOC for First Line Treatment of RET fusion-positive, Metastatic NSCLC | NSCLC stage III-IV | 1L |
|
Open | NCT04222972 |
CARMEN: Randomized, Open Label Phase 3 study of SAR408701 versus Docetaxel in Previously Treated metastatic nonsquamous NSCLC patients with CEACAM5 positive tumors | NSCLC | >1L |
|
Open | NCT04154956 |
CodeBreak200: A Phase III, Randomized, Open Label, Active-controlled, Study of AMG510 vs Docetaxel for the Treatment of Previously Treated Locally Advanced and Unresectable or Metastatic NSCLC subjects with Mutated KRAS p.G12C |
NSCLC stage IIIb-IV |
>=2L |
|
Open | |
ANAM-17-21: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ANAMORELIN HCL FOR THE TREATMENT OF MALIGNANCY ASSOCIATED WEIGHT LOSS AND ANOREXIA IN ADULT PATIENTS WITH ADVANCED NSCLC |
NSCLC stage III-IV |
All
|
|
Open | |
LUMINOSITY: Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-Met+ NSCLC |
NSCLC |
2-3L
|
|
Open |